Oncogenic Effect of Helicobacter Pylori, Prevention and Treatment Approach- A Review

Pooja Dosieah, Tan Luxuan, Zhang Zhen-Yu


Chronic gastritis has been long known to be related with gastric cancer. Most importantly, for most instances of gastric cancer, the fundamental reason for gastritis is ascribed to H. Pylori infection. Understanding the pathophysiologic mechanism that lead to gastric cancer is important for screening, prevention and treatment purposes. Gastritis can activate an oncogenic mechanism via the Correa cascade. However, studiePooja Dosieahs reported that the risk of gastric malignancy increments fundamentally when gastritis is combined with H. Pylori contamination. Other than the upper gastrointestinal tract, H. Pylori is additionally engaged with the pathogenesis of colorectal cancer. Treatment aiming at eradicating H. Pylori through the appropriate regimens is important. The triple standard therapy or the quadruple therapies are the universally accepted regimens. All infected patients should be subjected to H. Pylori treatment. An essential issue is to recognize those individuals at a greater possibility of developing H. Pylori infection including those with peptic ulcer illness, previous history of peptic ulcer disease, low-grade gastric mucosa-related lymphoid tissue (MALT) lymphoma, or a past history of endoscopic resection of early gastric disease.


Helicobacter pylori; Gastric cancer; Colorectal carcinogenesis; GERD.

Full Text:



. Moss, F. S. (2016). ‘The Clinical Evidence Linking Helicobacter pylori to Gastric Cancer’. Rhode Island: Elsevier Inc.

. HOUGHTON, J., & WANG, T. C. (2005). ‘Helicobacter pylori and Gastric Cancer: A New Paradigm for Inflammation-Associated Epithelial Cancers’. New York: American Gastroenterological Association.

. Testerman, T. L., & Morris, J. (2014). ‘Beyond the stomach: An updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment’. World Journal of Gastroenterology , 20 (36), 12781–12808.

. Abadi, A. T., & Kusters, J. G. (2016). ‘Management of Helicobacter pylori infections’. The Netherlands: CrossMark.

. CONTEDUCA, V., SANSONNO, D., LAULETTA, G., RUSSI, S., INGRAVALLO, G., & DAMMACCO, F. (2012). ‘H. pylori infection and gastric cancer: State of the art (Review). ‘International Journal of Oncology , 42, 5-18.

. Rocha, G. A., Rocha, A. M., Silva, L. D., Santos, A., Bocewicz, A. C., & Queiroz, R. d. (2003). ‘Transmission of Helicobacter pylori infection in families of preschool-aged children from Minas Gerais, Brazil. Tropical Medicine & International Health’ , 8 (2), 987–991.

. Wroblewski, L. E., Peek, R. M., & Wilson, K. T. (2010). ‘Helicobacter pylori and Gastric Cancer: Factors That Modulate Disease Risk’. Clinical Microbiology Reviews , 23 (4), 713-739.

. Zhang, W., Lu, H., & Graham, D. Y. (2014). ‘An Update on Helicobacter pylori as the Cause of Gastric Cancer’. Gastrointest Tumors , 155-165.

. Alzahrani, S., Lina, T. T., Gonzalez, J., Pinchuk, I. V., Beswick, E. J., & Reyes, V. E. (2014). ‘Effect of Helicobacter pylori on gastric epithelial cells’. World Journal of Gastroenterology , 67-80.

. Kim, S. S., Ruiz, V. E., Carroll, J. D., & Moss, S. F. (2011). ‘Helicobacter pylori in the pathogenesis of gastric cancer and gastric lymphoma.’ Author Manuscripts , 228-238.

. Sgouras, D. N., Trang, T. T., & Yamaoka, Y. (2015). ‘Pathogenesis of Helicobacter pylori Infection’. Helicobacter , 8-16.

. Zhang, R.-G., Duan, G.-C., Fan, Q.-T., & Chen, S.-Y. (2016). ‘Role of Helicobacter pylori infection in pathogenesis of gastric carcinoma’. World Journal of Gastrointestinal Pathophysiology , 7 (1), 97-107.

. Buti, L., Spooner, E., Van der Veen, A. G., Rappuoli, R., Covacci, A., & Ploegh, H. L. (2011). ‘Helicobacter pylori cytotoxin-associated gene A (CagA) subverts the apoptosis-stimulating protein of p53 (ASPP2) tumor suppressor pathway of the host.’ PNAS , 108 (22), 9238–9243.

. Boquet, P. (2012). ‘Intoxication strategy of Helicobacter pylori VacA toxin’. PubMed , 20 (4), 165-74.

. DN, H., AA, B., J, K., N, A., K, F., & MH, F. (2017). ‘Outer inflammatory protein a (OipA) of Helicobacter pylori is regulated by host cell contact and mediates CagA translocation and interleukin-8 response only in the presence of a functional cag pathogenicity island type IV secretion system.’ PubMed , 3-11.

. Matsuo, Y., Kido, Y., & Yamaoka, Y. (2017). ‘Helicobacter pylori Outer Membrane Protein-Related Pathogenesis’. Toxins , 9 (3), 101.

. Germán, C. M. (2014). ‘Hematologic manifestations of Helicobacter pylori infection’. World Journal of Gastroenterology , 20 (36), 12818–12838.

. Ramìrez, A. R., & Sánchez, R. S. (2008, 01 01). ‘PubMed Central. Retrieved from Science.gov: www.science.gov/topicpages/p/para+helicobacter+pylori.html’

. Grande, M., Cadeddu, F., Villa, M., Attinà, G. M., Marco, M. G., Casimiro, N., et al. (2008, July 5). ‘Helicobacter pylori and gastroesophageal reflux disease.’ World Journal of Surgical Oncology , 6-74.

. Cao, L., & Yu, J. (2015, April 22). ‘Effect of Helicobacter pylori Infection on the Composition of Gastric Microbiota in the Development of Gastric Cancer’. Gastrointest Tumors , 14-25.

. LEE, J., & O'MORAIN, C. (1997). ‘Who Should Be Treated for Helicobacter pylori Infection’? GASTROENTEROLOGY , 99-106.

. Mccoll, K. E., & El-Omar, E. (2000). ‘Mechanisms involved in the development of hypochlorhydria and pangastritis in Helicobacter pylori infection’. Springer Link , 373-384.

. Qian, B., Ma, S., Shang, L., Qian, J., & Zhang, G. (2011). ‘Effects of Helicobacter pylori Eradication on Gastroesophageal Reflux Disease’. Helicobacter , 255-265.

. Zagari, R. M., Romano, M., Ojetti, V., Stockbrugger, R., Gullini, S., Annibale, B., et al. (2015). ‘Guidelines for the management of Helicobacter pylori infection in Italy.’ Elsevier , 903-912.

. Kuipers, E. J. (2006). ‘Proton Pump Inhibitors and Helicobacter pylori Gastritis: Friends or Foes’? Pharmacology & Toxicology , 187-194.

. Mbulaiteye, S., Hisada, M., & El-Omar, E. (2009). ‘Helicobacter Pylori associated global gastric cancer burden’. PubMed , 1-14.

. Yong, X., Tang, B., Xiao, Y.-F., Xie, R., Qin, Y., Luo, G., et al. (2016). ‘Helicobacter pylori upregulates Nanog and Oct4 via Wnt/β-catenin signaling pathway to promote cancer stem cell-like properties in human gastric cancer’. Elsevier , 292-303.

. Kienesberger, S., Cox, L. M., Livanos, A., Zhang, X.-S., Chung, J., & Perez-Perez, G. I. (2016). ‘Gastric Helicobacter pylori infection affects local and distant microbial populations and host responses’. PubMed , 1395-1407.

. Blase, J. L., Campbell, P. T., Gapstur, S. M., Pawlita, M., Michel, A., Waterboer, T., et al. (2016). ‘Prediagnostic Helicobacter pylori Antibodies and Colorectal Cancer Risk in an Elderly, Caucasian Population.’ Helicobacter , 1523-5378.

. Sipponen, P., Kekki, M., Seppälä, K., & Siurala, M. (1996). ‘The relationships between chronic gastritis and gastric acid secretion’. PubMed , 1-103.

. Grivennikov, S. I., & Karin, M. (2010). ‘Inflammation and oncogenesis: a vicious connection’. Elsevier , 65-71.

. Rosadi, F., Fiorentini, C., & Fabbri, A. (2015). ‘Bacterial protein toxins in human cancers’. FEMS Pathogens and Disease , 105.

. Keates, S., Keates, A. C., Katchar, K., Peek, J. R., & Ciarén, K. P. (2007). ‘Helicobacter pylori Induces Up-Regulation of the Epidermal Growth Factor Receptor in AGS Gastric Epithelial Cells.’ The Journal of Infectious Diseases , 95-103.

. Haim, S. M., Doug, P. M., Aryeh, F. M., Yaron, N. M., Silvio, P. M., Zmira, S. P., et al. (2001). ‘Relationship Between Helicobacter pylori CagA Status and Colorectal Cancer’. THE AMERICAN JOURNAL OF GASTROENTEROLOGY , 1-5.

. Papastergiou, V., Karatapanis, S., & Georgopoulos, S. D. (2016). ‘Helicobacter pylori and colorectal neoplasia: Is there a causal link? ‘World Journal of Gastroenterology , 649-658.

. Yamaoka, Y., & Graham, D. Y. (2014). ‘Helicobacter pylori virulence and cancer pathogenesis’. PubMed , 1487-1500.

. Hyun, J. J. (2016). ‘The Effect of H. pylori Infection on the Gastric Microbiota’. Springer Science+Business Media Singapore , 978-981.

. Parsons, B. N., Ijaz, U. Z., D’Amore, R., D. Burkitt, M., Eccles, R., Lenzi, L., et al. (2017). ‘Comparison of the human gastric microbiota in hypochlorhydric states arising as a result of Helicobacter pylori-induced atrophic gastritis, autoimmune atrophic gastritis and proton pump inhibitor use.’ PLOS Pathogens , 10-71.

. Ford, A. C., Forman, D., Hunt, R. H., Yuan, Y., & Moayyedi, P. (2014). ‘Helicobacter pylorieradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals.’ BMJ , 1-13.

. E M El‐, O. (2006). ‘Mechanisms of increased acid secretion after eradication of Helicobacter pylori infection’. PubMed , 144-146.

. Wu, W. M., Yang, Y. S., & Peng, L. H. (2013). ‘Microbiota in the stomach: New insights’. Journal Of Digestive Diseases , 11-51.

. Noto, J. M., & Peek Jr, R. M. (2017). ‘The gastric microbiome, its interaction with Helicobacter pylori, and its potential role in the progression to stomach cancer’. PLOS Pathogens , 10-71.

. Heimesaat, M. M., Fischer, A., Plickert, R., Wiedemann, T., Loddenkemper, C., Göbel, U. B., et al. (2014). ‘Helicobacter pylori Induced Gastric Immunopathology Is Associated with Distinct Microbiota Changes in the Large Intestines of Long-Term Infected Mongolian Gerbils.’ PLOS One , 10-71.

. Shrestha, R., Koirala, K., Shiv Raj, K. C., & Batajoo, K. H. (2014). ‘Helicobacter Pylori Infection Among Patients with Upper Gastrointestinal Symptoms: Prevalence and Relation to Endoscopy Diagnosis and Histopathology’. Journal of family medicine and primary care , 154-158.

. Luigi, S. (2017). ‘Helicobacter Pylori Infection Medication.’ Medscape , 2-14.

. Luigi, S. (2017). ‘Helicobacter Pylori Infection Treatment & Management’. Medscape , 2-15.

. Ghotaslou, R., Leylabadlo, H. E., & Asl, Y. M. (2015).’ Prevalence of antibiotic resistance in Helicobacter pylori: A recent literature review’. World Journal of Methodology , 164-174.

. Chen, Y.-I., & Fallone, C. A. (2015). ‘A 14-day course of triple therapy is superior to a 10-day course for the eradication of Helicobacter pylori: A Canadian study conducted in a ‘real world’ setting’. Canadian Journal of Gastroenterol Hepatol , 7-10.

. Clinical, N. (2016, February 5). ‘Combination Regimens for Eradication of H. pylori. Retrieved 9 10, 2014, from MIMS: https://www.mims.co.uk/combination-regimens-eradication-h-pylori-nice-guideline/gi-tract/article/882106’

. Di Mario, F., Cavallaro, L., & Scarpignato, C. (2006). 'Rescue' Therapies for the Management of Helicobacter pylori Infection. Karger , 113-130.

. Siddalingam, R., & Chidambaram, K. (2017). ‘Helicobacter pylori — Current Therapy and Future. Kuala Lumpur, Malaysia:’ IntechOpen.

. Sokic-Milutinovic, A., Alempijevic, T., & Milosavljevic, T. (2015). ‘Role of Helicobacter pylori infection in gastric carcinogenesis: Current knowledge and future directions’. World Journal of Gastroenterology , 54-72.

. Kalali, B., Mejías-Luque, R., Javaheri, A., & Gerhard, M. (2014). ‘H. pylori Virulence Factors: Influence on Immune System and Pathology’. Hindawi , 1-9.

. Roesler, B. M., Costa, S. C., & Zeitune, J. M. (2012). ‘Eradication Treatment of Helicobacter pylori Infection: Its Importance and Possible Relationship in Preventing the Development of Gastric Cancer’. Hindawi , 1-9.


  • There are currently no refbacks.





About IJSBAR | Privacy PolicyTerms & Conditions | Contact Us | DisclaimerFAQs 

IJSBAR is published by (GSSRR).